Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cuprina Holdings (Cayman)CUPR -2.51%10 Debt-to-Equity is 0.10 as of Dec. 2025. GuruFocus rates CUPR with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Cuprina Holdings (Cayman) ranks better than 67.42% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cuprina Holdings (Cayman)'s Debt-to-Equity or its related term are showing as below:
CUPR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.25 Med: -0.06 Max: 0.1
Current: 0.1
During the past 5 years, the highest Debt-to-Equity Ratio of Cuprina Holdings (Cayman) was 0.10. The lowest was -0.25. And the median was -0.06.
CUPR's Debt-to-Equity is ranked better than 67.42% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs CUPR: 0.10
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cuprina Holdings (Cayman) Debt-to-Equity Related Terms
Cuprina Holdings (Cayman) Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUPR vs BNGO, UEEC, FEMY: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Cuprina Holdings (Cayman)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuprina Holdings (Cayman) Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cuprina Holdings (Cayman)'s Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cuprina Holdings (Cayman)'s Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cuprina Holdings (Cayman) (CUPR) has a Debt-to-Equity of 0.10 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cuprina Holdings (Cayman) and its competitors. According to the industry distribution chart, Cuprina Holdings (Cayman) ranks #230 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 32.6%.
Is Cuprina Holdings (Cayman)'s Debt-to-Equity too high?
Cuprina Holdings (Cayman)'s current Debt-to-Equity is 0.10. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Cuprina Holdings (Cayman)'s value of 0.10 is 55.6% below this industry median. Based on the distribution chart, Cuprina Holdings (Cayman) ranks #230 out of 706 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s Debt-to-Equity compare to BNGO and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Cuprina Holdings (Cayman) ranks #230 out of 706 companies for Debt-to-Equity. This puts Cuprina Holdings (Cayman) in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Cuprina Holdings (Cayman)'s value of 0.10 is 55.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cuprina Holdings (Cayman)'s current Debt-to-Equity of 0.10 is 55.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cuprina Holdings (Cayman) and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuprina Holdings (Cayman)'s current Debt-to-Equity is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current Debt-to-Equity of 0.10. The current Debt-to-Equity is 0.10 and 55.6% below the Medical Devices & Instruments industry median of 0.23. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current Debt-to-Equity is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score
Get the complete analysis for CUPR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUPR has been successfully added to your 
